Publicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (39)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

  3. The ‘BCLC upon progression’ classification: After repeated validation, it is time to incorporate it in trial design

    Liver International

2023

  1. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  2. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

    Frontiers in Pharmacology

  3. Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming

    Journal of Hepatology, Vol. 79, Núm. 3, pp. 728-740

  4. Impacto del manejo en urgencias en la evolución de los pacientes con trombosis venosa superficial aislada de miembros inferiores: subanálisis del estudio ALTAMIRA

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 2, pp. 109-116

  5. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  6. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  7. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

    Frontiers in Pharmacology, Vol. 14

2022

  1. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease

    Gut, Vol. 71, Núm. 9, pp. 1856-1866

  2. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  3. Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission

    Medicina Clinica

  4. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis

    Hepatology International, Vol. 15, Núm. 4, pp. 1006-1017

  2. Integrated Multiomics Reveals Glucose Use Reprogramming and Identifies a Novel Hexokinase in Alcoholic Hepatitis

    Gastroenterology, Vol. 160, Núm. 5, pp. 1725-1740.e2

  3. Persistent retinal microvascular impairment in covid-19 bilateral pneumonia at 6-months follow-up assessed by optical coherence tomography angiography

    Biomedicines, Vol. 9, Núm. 5

  4. Retinal microvascular impairment in covid-19 bilateral pneumonia assessed by optical coherence tomography angiography

    Biomedicines, Vol. 9, Núm. 3, pp. 1-14

  5. Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage

    Hepatology, Vol. 74, Núm. 5, pp. 2791-2807

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227